| Autor: |
d’Aquino, Andrea I., Maikawa, Caitlin L., Nguyen, Leslee T., Lu, Katie, Hall, Ian A., Jons, Carolyn K., Kasse, Catherine M., Yan, Jerry, Prossnitz, Alexander N., Chang, Enmian, Baker, Sam W., Hovgaard, Lars, Steensgaard, Dorte B., Andersen, Hanne B., Simonsen, Lotte, Appel, Eric A. |
| Zdroj: |
Cell Reports Medicine; November 2023, Vol. 4 Issue: 11 |
| Abstrakt: |
Glucagon-like peptide-1 (GLP-1) is an incretin hormone and neurotransmitter secreted from intestinal L cells in response to nutrients to stimulate insulin and block glucagon secretion in a glucose-dependent manner. Long-acting GLP-1 receptor agonists (GLP-1 RAs) have become central to treating type 2 diabetes (T2D); however, these therapies are burdensome, as they must be taken daily or weekly. Technological innovations that enable less frequent administrations would reduce patient burden and increase patient compliance. Herein, we leverage an injectable hydrogel depot technology to develop a GLP-1 RA drug product capable of months-long GLP-1 RA delivery. Using a rat model of T2D, we confirm that one injection of hydrogel-based therapy sustains exposure of GLP-1 RA over 42 days, corresponding to a once-every-4-months therapy in humans. Hydrogel therapy maintains management of blood glucose and weight comparable to daily injections of a leading GLP-1 RA drug. This long-acting GLP-1 RA treatment is a promising therapy for more effective T2D management. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
